Senin, 05 Mei 2014
anechoic effect
boards of directors
conflicts of interest
Gates Foundation
Genentech
health care foundations
health care prices
Lancet
medical journals
Procter and Gamble
UCSF
Abort, Retry, Fail? - Lancet Avoided Much Recent Unpleasantness in Reporting on New Gates Foundation CEO (Including Her Defense of $55,000 a Year for Bevacizumab)
The April 26, 2014 issue of the prestigious journal Lancet used two full pages and two separate articles by the same author to discuss the a...